Scientists used IBM's R2 Heron quantum processor to predict the secondary protein structure of a 60-nucleotide-long mRNA ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Six months into Donald Trump’s second term, his administration is at war with the federal judiciary, evading court orders ...

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

The top public health officials during Trump's first term praised mRNA vaccines. In the second term, officials seem to be retreating from them.

The U.S. health secretary ordered an end to new mRNA development efforts just after UTMB published new research showing its ...

Adams, who served as surgeon general during the first Trump administration, said Kennedy's assertions about the efficacy of ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Shares of COVID-19 vaccine maker Moderna MRNA rose 13.1% on Jan 2, after analysts at Oppenheimer recently upgraded the stock’s recommendation to Outperform, with a price target of $142 per share.